我國乳腺癌預防若干問題的思考_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

瞿亞軍 ¹ ,  呂青 ²

1. ;
2. ;

Corresponding?author：

呂青, Email: lqlq1963@163.com

Keywords：

DOI：

10.7507/1007-9424.202009088

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 瞿亞軍, 呂青. 我國乳腺癌預防若干問題的思考. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2020, 27(11): 1334-1339. doi: 10.7507/1007-9424.202009088 Copy

1.	李賀, 鄭榮壽, 張思維, 等. 2014年中國女性乳腺癌發病與死亡分析. 中華腫瘤雜志, 2018, 40(3): 166-171.
2.	Fan L, Strasser-Weippl K, Li JJ, et al. Breast cancer in China. Lancet Oncol, 2014, 15(7): e279-e289.
3.	陳萬青, 鄭榮壽. 中國女性乳腺癌發病死亡和生存狀況. 中國腫瘤臨床, 2015, 42(13): 668-674.
4.	國家統計局. 中華人民共和國2018年國民經濟和社會發展統計公報. 2019. http://www.stats.gov.cn/tjsj/zxfb/201902/t20190228_1651265.html.
5.	世界人口網. http://www.renkou.org.cn/.
6.	Song QK, Wang XL, Zhou XN, et al. Breast cancer challenges and screening in China: lessons from current registry data and population screening studies. Oncologist, 2015, 20(7): 773-779.
7.	DeSantis CE, Fedewa SA, Goding Sauer A, et al. Breast cancer statistics, 2015: Convergence of incidence rates between black and white women. CA Cancer J Clin, 2016, 66(1): 31-42.
8.	黃育北, 佟仲生, 陳可欣, 等. 《中國女性乳腺癌篩查指南》解讀(精簡版). 中國腫瘤臨床, 2019, 46(9): 433-441.
9.	Huang Y, Dai H, Song F, et al. Preliminary effectiveness of breast cancer screening among 1. 22 million Chinese females and different cancer patterns between urban and rural women. Sci Rep, 2016, 6: 39459.
10.	陳萬青, 李霓, 石菊芳, 等. 中國城市癌癥早診早治項目進展. 中國腫瘤, 2019, 28(1): 23-25.
11.	婦幼健康司. 中國婦幼健康事業發展報告(2019). 國家衛生健康委員會官網, 2019 年5 月. http://www.nhc.gov.cn/fys/s7901/201905/bbd8e2134a7e47958c5c9ef032e1dfa2.shtml.
12.	Chen WQ, Zheng RS, Zhang SW, et al. Report of incidence and mortality in china cancer registries, 2008. Chin J Cancer Res, 2012, 24(3): 171-180.
13.	Chen WQ, Zheng RS, Zhang SW, et al. Report of cancer incidence and mortality in China, 2010. Ann Transl Med, 2014, 2(7): 61.
14.	Chen WQ, Zheng RS, Zuo TT, et al. National cancer incidence and mortality in China, 2012. Chin J Cancer Res, 2016, 28(1): 1-11.
15.	Chen WQ, Zheng RS, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin, 2016, 66(2): 115-132.
16.	Wang BH, He MF, Wang LM, et al. Breast cancer screening among adult women in China, 2010. Prev Chronic Dis, 2013, 10: E183.
17.	包鶴齡, 王臨虹, 王麗敏, 等. 中國 2013 年 35~69 歲女性人群子宮頸癌和乳腺癌篩查率及影響因素研究. 中華流行病學雜志, 2018, 39(2): 208-212.
18.	徐兵河. 乳腺癌的明天是什么?. 醫脈通. 2018 年 8 月 21 日. http://news.medlive.cn/cancer/info-progress/show-147795_53.html.
19.	Breen N, Gentleman JF, Schiller JS. Update on mammography trends: comparisons of rates in 2000, 2005, and 2008. Cancer, 2011, 117(10): 2209-2218.
20.	楊非, 黃源, 應桂英, 等. 四川省基層醫療衛生服務機構開展宮頸癌和乳腺癌篩查能力的調查. 中國全科醫學, 2014, 17(18): 2118-2122.
21.	Onega T, Beaber EF, Sprague BL, et al. Breast cancer screening in an era of personalized regimens: a conceptual model and National Cancer Institute initiative for risk-based and preference-based approaches at a population level. Cancer, 2014, 120(19): 2955-2964.
22.	馮雅靖, 方利文, 王卓群, 等. 在中國農村地區婦女人群中整合開展主要慢性病與“兩癌”篩查的可行性分析. 中國慢性病預防與控制, 2016, 24(6): 466-469.
23.	中國抗癌協會乳腺癌專業委員會. 中國抗癌協會乳腺癌診治指南與規范(2019 版). 中國癌癥雜志, 2019, 29(8): 609-680.
24.	中國抗癌協會國家腫瘤臨床醫學研究中心(天津醫科大學腫瘤醫院). 中國女性乳腺癌篩查指南. 中國腫瘤臨床, 2019, 46(9): 430-432.
25.	Zhang J, Sun J, Chen J, et al. Comprehensive analysis of BRCA1 and BRCA2 germline mutations in a large cohort of 5 931 Chinese women with breast cancer. Breast Cancer Res Treat, 2016, 158(3): 455-462.
26.	Lang GT, Shi JX, Hu X, et al. The spectrum of BRCA mutations and characteristics of BRCA-associated breast cancers in China: Screening of 2 991 patients and 1, 043 controls by next-generation sequencing. Int J Cancer, 2017, 141(1): 129-142.
27.	Yao L, Sun J, Zhang J, et al. Breast cancer risk in Chinese women with BRCA1 or BRCA2 mutations. Breast Cancer Res Treat, 2016, 156(3): 441-445.
28.	Howell A, Anderson AS, Clarke RB, et al. Risk determination and prevention of breast cancer. Breast Cancer Res, 2014, 16(5): 446.
29.	Costantino JP, Gail MH, Pee D, et al. Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst, 1999, 91(18): 1541-1548.
30.	Schonfeld SJ, Pee D, Greenlee RT, et al. Effect of changing breast cancer incidence rates on the calibration of the Gail model. J Clin Oncol, 2010, 28(14): 2411-241.
31.	NCCN. NCCN clinical practice guidlines: Breast cancer risk reducetion, version 1.2020. Fort Washington: NCCN, Inc, 2020.
32.	Visvanathan K, Fabian CJ, Bantug E, et al. Use of endocrine therapy for breast cancer risk reduction: ASCO Clinical practice guideline update. J Clin Oncol, 2019, 37(33): 3152-3165.
33.	宋豐舉, 劉雪鷗, 黃育北, 等. 中國女性良性乳腺疾病的流行現狀、危險因素及對乳腺癌篩查效果的影響研究. 成都: 全國腫瘤流行病學和腫瘤病因學學術會議論文集, 2015.
34.	Cheng J, Qiu S, Raju U, et al. Benign breast disease heterogeneity: association with histopathology, age, and ethnicity. Breast Cancer Res Treat, 2008, 111(2): 289-296.
35.	新浪網. 中國人口協會發布中國乳腺疾病調查報告. 2010 年 2 月 1 日. http://eladies.sina.com.cn/nx/2010/0201/1059966477.shtml.
36.	Hartmann LC, Sellers TA, Frost MH, et al. Benign breast disease and the risk of breast cancer. N Engl J Med, 2005, 353(3): 229-237.
37.	American Cancer Society. Breast cancer facts & figures 2019-2020. Atlanta: American Cancer Society, Inc. 2019.
38.	Pankratz VS, Degnim AC, Frank RD, et al. Model for individualized prediction of breast cancer risk after a benign breast biopsy. J Clin Oncol, 2015, 33(8): 923-929.
39.	Wang Y, Gao Y, Battsend M, et al. Development of a risk assessment tool for projecting individualized probabilities of developing breast cancer for Chinese women. Tumour Biol, 2014, 35(11): 10861-10869.
40.	Dorjgochoo T, Deming SL, Gao YT, et al. History of benign breast disease and risk of breast cancer among women in China: a case-control study. Cancer Causes Control, 2008, 19(8): 819-828.
41.	Jacobs TW, Byrne C, Colditz G, et al. Radial scars in benign breast-biopsy specimens and the risk of breast cancer. N Engl J Med, 1999, 340(6): 430-436.
42.	張安秦, 夏建紅, 王頎, 等. 廣東地區婦女乳腺癌高危因素分析與對策. 南方醫科大學學報, 2009, 29(7): 1451-1453.
43.	Visvanathan K, Hurley P, Bantug E, et al. Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol, 2013, 31(23): 2942-296.
44.	ACS. Breast cancer prevention and early detection. American Cancer Society, 2020. https://www.cancer.org/content/dam/CRC/PDF/Public/8579.00.pdf.
45.	American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins—Gynecology. Practice bulletin No. 164: Diagnosis and management of benign breast disorders. Obstet Gynecol, 2016, 127(6): e141-e156.
46.	Cuzick J, DeCensi A, Arun B, et al. Preventive therapy for breast cancer: a consensus statement. Lancet Oncol, 2011, 12(5): 496-503.
47.	Lavoué V, Fritel X, Antoine M, et al. Clinical practice guidelines from the French College of Gynecologists and Obstetricians (CNGOF): benign breast tumors - short text. Eur J Obstet Gynecol Reprod Biol, 2016, 200: 16-23.
48.	Vogel VG. Ongoing data from the breast cancer prevention trials: opportunity for breast cancer risk reduction. BMC Med, 2015, 13: 63.

1. 李賀, 鄭榮壽, 張思維, 等. 2014年中國女性乳腺癌發病與死亡分析. 中華腫瘤雜志, 2018, 40(3): 166-171.
2. Fan L, Strasser-Weippl K, Li JJ, et al. Breast cancer in China. Lancet Oncol, 2014, 15(7): e279-e289.
3. 陳萬青, 鄭榮壽. 中國女性乳腺癌發病死亡和生存狀況. 中國腫瘤臨床, 2015, 42(13): 668-674.
4. 國家統計局. 中華人民共和國2018年國民經濟和社會發展統計公報. 2019. http://www.stats.gov.cn/tjsj/zxfb/201902/t20190228_1651265.html.
5. 世界人口網. http://www.renkou.org.cn/.
6. Song QK, Wang XL, Zhou XN, et al. Breast cancer challenges and screening in China: lessons from current registry data and population screening studies. Oncologist, 2015, 20(7): 773-779.
7. DeSantis CE, Fedewa SA, Goding Sauer A, et al. Breast cancer statistics, 2015: Convergence of incidence rates between black and white women. CA Cancer J Clin, 2016, 66(1): 31-42.
8. 黃育北, 佟仲生, 陳可欣, 等. 《中國女性乳腺癌篩查指南》解讀(精簡版). 中國腫瘤臨床, 2019, 46(9): 433-441.
9. Huang Y, Dai H, Song F, et al. Preliminary effectiveness of breast cancer screening among 1. 22 million Chinese females and different cancer patterns between urban and rural women. Sci Rep, 2016, 6: 39459.
10. 陳萬青, 李霓, 石菊芳, 等. 中國城市癌癥早診早治項目進展. 中國腫瘤, 2019, 28(1): 23-25.
11. 婦幼健康司. 中國婦幼健康事業發展報告(2019). 國家衛生健康委員會官網, 2019 年5 月. http://www.nhc.gov.cn/fys/s7901/201905/bbd8e2134a7e47958c5c9ef032e1dfa2.shtml.
12. Chen WQ, Zheng RS, Zhang SW, et al. Report of incidence and mortality in china cancer registries, 2008. Chin J Cancer Res, 2012, 24(3): 171-180.
13. Chen WQ, Zheng RS, Zhang SW, et al. Report of cancer incidence and mortality in China, 2010. Ann Transl Med, 2014, 2(7): 61.
14. Chen WQ, Zheng RS, Zuo TT, et al. National cancer incidence and mortality in China, 2012. Chin J Cancer Res, 2016, 28(1): 1-11.
15. Chen WQ, Zheng RS, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin, 2016, 66(2): 115-132.
16. Wang BH, He MF, Wang LM, et al. Breast cancer screening among adult women in China, 2010. Prev Chronic Dis, 2013, 10: E183.
17. 包鶴齡, 王臨虹, 王麗敏, 等. 中國 2013 年 35~69 歲女性人群子宮頸癌和乳腺癌篩查率及影響因素研究. 中華流行病學雜志, 2018, 39(2): 208-212.
18. 徐兵河. 乳腺癌的明天是什么?. 醫脈通. 2018 年 8 月 21 日. http://news.medlive.cn/cancer/info-progress/show-147795_53.html.
19. Breen N, Gentleman JF, Schiller JS. Update on mammography trends: comparisons of rates in 2000, 2005, and 2008. Cancer, 2011, 117(10): 2209-2218.
20. 楊非, 黃源, 應桂英, 等. 四川省基層醫療衛生服務機構開展宮頸癌和乳腺癌篩查能力的調查. 中國全科醫學, 2014, 17(18): 2118-2122.
21. Onega T, Beaber EF, Sprague BL, et al. Breast cancer screening in an era of personalized regimens: a conceptual model and National Cancer Institute initiative for risk-based and preference-based approaches at a population level. Cancer, 2014, 120(19): 2955-2964.
22. 馮雅靖, 方利文, 王卓群, 等. 在中國農村地區婦女人群中整合開展主要慢性病與“兩癌”篩查的可行性分析. 中國慢性病預防與控制, 2016, 24(6): 466-469.
23. 中國抗癌協會乳腺癌專業委員會. 中國抗癌協會乳腺癌診治指南與規范(2019 版). 中國癌癥雜志, 2019, 29(8): 609-680.
24. 中國抗癌協會國家腫瘤臨床醫學研究中心(天津醫科大學腫瘤醫院). 中國女性乳腺癌篩查指南. 中國腫瘤臨床, 2019, 46(9): 430-432.
25. Zhang J, Sun J, Chen J, et al. Comprehensive analysis of BRCA1 and BRCA2 germline mutations in a large cohort of 5 931 Chinese women with breast cancer. Breast Cancer Res Treat, 2016, 158(3): 455-462.
26. Lang GT, Shi JX, Hu X, et al. The spectrum of BRCA mutations and characteristics of BRCA-associated breast cancers in China: Screening of 2 991 patients and 1, 043 controls by next-generation sequencing. Int J Cancer, 2017, 141(1): 129-142.
27. Yao L, Sun J, Zhang J, et al. Breast cancer risk in Chinese women with BRCA1 or BRCA2 mutations. Breast Cancer Res Treat, 2016, 156(3): 441-445.
28. Howell A, Anderson AS, Clarke RB, et al. Risk determination and prevention of breast cancer. Breast Cancer Res, 2014, 16(5): 446.
29. Costantino JP, Gail MH, Pee D, et al. Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst, 1999, 91(18): 1541-1548.
30. Schonfeld SJ, Pee D, Greenlee RT, et al. Effect of changing breast cancer incidence rates on the calibration of the Gail model. J Clin Oncol, 2010, 28(14): 2411-241.
31. NCCN. NCCN clinical practice guidlines: Breast cancer risk reducetion, version 1.2020. Fort Washington: NCCN, Inc, 2020.
32. Visvanathan K, Fabian CJ, Bantug E, et al. Use of endocrine therapy for breast cancer risk reduction: ASCO Clinical practice guideline update. J Clin Oncol, 2019, 37(33): 3152-3165.
33. 宋豐舉, 劉雪鷗, 黃育北, 等. 中國女性良性乳腺疾病的流行現狀、危險因素及對乳腺癌篩查效果的影響研究. 成都: 全國腫瘤流行病學和腫瘤病因學學術會議論文集, 2015.
34. Cheng J, Qiu S, Raju U, et al. Benign breast disease heterogeneity: association with histopathology, age, and ethnicity. Breast Cancer Res Treat, 2008, 111(2): 289-296.
35. 新浪網. 中國人口協會發布中國乳腺疾病調查報告. 2010 年 2 月 1 日. http://eladies.sina.com.cn/nx/2010/0201/1059966477.shtml.
36. Hartmann LC, Sellers TA, Frost MH, et al. Benign breast disease and the risk of breast cancer. N Engl J Med, 2005, 353(3): 229-237.
37. American Cancer Society. Breast cancer facts & figures 2019-2020. Atlanta: American Cancer Society, Inc. 2019.
38. Pankratz VS, Degnim AC, Frank RD, et al. Model for individualized prediction of breast cancer risk after a benign breast biopsy. J Clin Oncol, 2015, 33(8): 923-929.
39. Wang Y, Gao Y, Battsend M, et al. Development of a risk assessment tool for projecting individualized probabilities of developing breast cancer for Chinese women. Tumour Biol, 2014, 35(11): 10861-10869.
40. Dorjgochoo T, Deming SL, Gao YT, et al. History of benign breast disease and risk of breast cancer among women in China: a case-control study. Cancer Causes Control, 2008, 19(8): 819-828.
41. Jacobs TW, Byrne C, Colditz G, et al. Radial scars in benign breast-biopsy specimens and the risk of breast cancer. N Engl J Med, 1999, 340(6): 430-436.
42. 張安秦, 夏建紅, 王頎, 等. 廣東地區婦女乳腺癌高危因素分析與對策. 南方醫科大學學報, 2009, 29(7): 1451-1453.
43. Visvanathan K, Hurley P, Bantug E, et al. Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol, 2013, 31(23): 2942-296.
44. ACS. Breast cancer prevention and early detection. American Cancer Society, 2020. https://www.cancer.org/content/dam/CRC/PDF/Public/8579.00.pdf.
45. American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins—Gynecology. Practice bulletin No. 164: Diagnosis and management of benign breast disorders. Obstet Gynecol, 2016, 127(6): e141-e156.
46. Cuzick J, DeCensi A, Arun B, et al. Preventive therapy for breast cancer: a consensus statement. Lancet Oncol, 2011, 12(5): 496-503.
47. Lavoué V, Fritel X, Antoine M, et al. Clinical practice guidelines from the French College of Gynecologists and Obstetricians (CNGOF): benign breast tumors - short text. Eur J Obstet Gynecol Reprod Biol, 2016, 200: 16-23.
48. Vogel VG. Ongoing data from the breast cancer prevention trials: opportunity for breast cancer risk reduction. BMC Med, 2015, 13: 63.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

我國乳腺癌預防若干問題的思考

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content